US Medicare Losing Money Faster Than Ever

9 June 1996

With a US Congressional Budget Office report expected to confirm warnings that the Medicare program is losing money faster than ever, the debate over the scheme is heating up again. The New York Times feels that the control of Congress and the result of the presidential election could turn on the outcome.

Congressional Republican leaders plan to blame the President, noting he vetoed legislation last year that would have restrained Medicare spending, and the White House is likely to accuse Republicans of trying to cut health care for retirees to raise money for tax cuts for the rich.

However, the carping overlooks serious proposals on both sides that were offering this past spring to stop the slide into bankruptcy. Outside experts feel the plans offer a basis for a compromise that would stabilize the program, the NY Times says, and no-one now expects such a compromise to occur because officials on both sides feel their positions are politically advantageous, and that a compromise would cost them their edge.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight